Novartis Bags Another Bolt-On With Cadent Buy
Pays $210m Upfront For Cognitive Disorder Biotech
Having worked with the Cambridge, MA-based neurology specialist for five years on a treatment-resistant depression drug, Novartis has decided to buy all of Cadent in a deal that could be worth up to $770m.
